Skip to main content

Table 2 Demographics and baseline characteristics of patients with COVID-19

From: Clinical and imaging findings of discharged patients with SARS-CoV-2 positive anal swab samples: a descriptive study

 

Total (N = 42)

Anal swab test positive (n = 6)

Anal swab test negative (n = 36)

P Valuea

Sex

 Female

25(59.5%)

6(100.0%)

19(52.8%)

0.031

 Male

17(40.5%)

0(0.0%)

17(47.2%)

 

Age, median (IQR), y

40(30.8 ~ 46.0)

28.5(13.3 ~ 50.5)

42(32 ~ 46)

0.250

 >50

9(21.4%)

1(16.7%)

8(22.2%)

0.762

 ≤ 50

33(78.6%)

5(83.3%)

28(77.8%)

 

BMI, median (IQR)

24.4(22.2 ~ 25.7)

24.6(16.0 ~ 27.9)

24.1(22.2 ~ 25.6)

1.000

Epidemiology

 Direct exposure history

22(52.4%)

2(33.3%)

20(55.6%)

0.148

 Indirect exposure history

6(14.3%)

0(0.0%)

6(16.7%)

 

 Family outbreak

14(33.3%)

4(66.7%)

10(27.8%)

 

Incubation period, median (IQR), d

7(3 ~ 10)

9(4.5 ~ 11.3)

6.5(3 ~ 10)

0.320

Onset of symptom to, median (IQR), d

 Hospital admission

3.5(2 ~ 6)

3.0(2 ~ 5.5)

3.5(2 ~ 6)

0.697

 Anal swab test

27(25 ~ 32.3)

26.5(21.5 ~ 35.3)

27(25 ~ 32.3)

0.836

Signs and symptoms

 Fever

29(69.0%)

3(50.0%)

26(72.2%)

0.281

 Maximum temperature, median (IQR), °C

37.7(36.8 ~ 38.5)

37.2(36.1 ~ 38.2)

37.9(37.0 ~ 38.7)

0.235

 <37·3

13(31.0%)

3(50.0%)

10(27.8%)

0.541

 37·3–38

14(33.3%)

2(33.3%)

12(33.3%)

 

 38·1–39

8(19.0%))

0(0.0%)

8(22.2%)

 

 >39

7(16.7%)

1(16.7%)

6(16.7%)

 

 Cough

35(83.3%)

4(66.7%)

31(86.1%)

0.242

 Dyspnea

3(7.1%)

1(16.7%)

2(5.6%)

0.333

 Fatigue

3(7.1%)

1(16.7%)

2(5.6%)

0.333

 Myalgia

5(11.9%)

0(0.0%)

5(13.9%)

0.336

 Headache

4(9.5%)

0(0.0%)

4(11.1%)

0.396

 Nausea and vomiting

1(2.4%)

0(0.0%)

1(2.8%)

0.683

 Diarrhea

6(14.3%)

0(0.0%)

6(16.7%)

0.285

 No symptoms

4(9.5%)

2(33.3%)

2(5.6%)

0.034

Comorbidities

 Diabetes

2(4.8%)

0(0.0%)

2(5.6%)

0.558

 Hypertension

2(4.8%)

0(0.0%)

2(5.6%)

0.558

 Hepatitis or liver cirrhosis

2(4.8%)

0(0.0%)

2(5.6%)

0.558

 Chronic renal failure

1(2.4%)

0(0.0%)

1(2.8%)

0.683

 Malignancy

1(2.4%)

0(0.0%)

1(2.8%)

0.683

 Digestive diseases

3(7.1%)

1(16.7%)

2(5.6%)

0.333

Clinical type

 Mild type

2(4.8%)

1(16.7%)

1(2.8%)

0.701

 Common type

30(71.4%)

3(50.0%)

27(75.0%)

 

 Severe type

7(16.7%)

2(33.3%)

5(13.9%)

 

 Critical type

3(7.1%)

0(0.0%)

3(8.3%)

 

 Mild + Common type

32(76.2%)

4(66.7%)

28(77.8%)

0.558

 Severe + Critical type

10(23.8)

2(33.3%)

8(22.2%)

 

Treatment

 Antibiotic

29(69.0%)

3(50.0%)

26 (72.2%)

0.281

 Duration of antibiotic

6.5(0 ~ 8.3)

2.5(0 ~ 10.5)

7.0(0 ~ 8)

0.562

 Glucocorticoid

29(69.0%)

4(66.7%)

25(69.4%)

0.892

 Duration of glucocorticoid

4(0 ~ 5)

4.5(0 ~ 6.5)

4(0 ~ 5)

0.739

 Non-Invasive Ventilation

3(7.1%)

1(16.7%)

2(5.6%)

0.333

 Duration of throat swab positive, median (IQR), d

7.5(5 ~ 10.3)

10.0(7.3 ~ 12.3)

7.0(3 ~ 10)

0.208

 Duration of fever, median (IQR), d

5(0.8 ~ 9.3)

1(0 ~ 6.3)

6(2 ~ 9.8)

0.120

 Duration of major symptoms (except fever), median (IQR), d

8.5(3.8 ~ 13.3)

4.5(0 ~ 5.5)

10.5(4.3 ~ 14)

0.022

 Hospital stays, median (IQR), d

12.5(9 ~ 18)

14.5(11 ~ 20.3)

11.5(9 ~ 17.5)

0.471

  1. a P values indicate differences between anal swab test positive and negtive patients. P < .05 was considered statistically significant